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ABSTRACT
Metabolic adaptation has emerged as a hallmark of cancer and a promising 
therapeutic target, as rapidly proliferating cancer cells adapt their metabolism 
increasing nutrient uptake and reorganizing metabolic fluxes to support biosynthesis. 
The transcription factor p73 belongs to the p53-family and regulates tumorigenesis 
via its two N-terminal isoforms, with (TAp73) or without (ΔNp73) a transactivation 
domain. TAp73 acts as tumor suppressor, at least partially through induction of cell 
cycle arrest and apoptosis and through regulation of genomic stability. Here, we 
sought to investigate whether TAp73 also affects metabolic profiling of cancer cells. 
Using high throughput metabolomics, we unveil a thorough and unexpected role for 
TAp73 in promoting Warburg effect and cellular metabolism. TAp73-expressing cells 
show increased rate of glycolysis, higher amino acid uptake and increased levels 
and biosynthesis of acetyl-CoA. Moreover, we report an extensive TAp73-mediated 
upregulation of several anabolic pathways including polyamine and synthesis of 
membrane phospholipids. TAp73 expression also increases cellular methyl-donor 
S-adenosylmethionine (SAM), possibly influencing methylation and epigenetics, and 
promotes arginine metabolism, suggestive of a role in extracellular matrix (ECM) 
modeling. In summary, our data indicate that TAp73 regulates multiple metabolic 
pathways that impinge on numerous cellular functions, but that, overall, converge 
to sustain cell growth and proliferation.
INTRODUCTION
p73 is a transcription factor and a member of the 
p53-family [1–3]. p73 is transcribed in two alternative 
N-terminal isoforms: the use of an upstream promoter 
allows expression of transcriptional competent TAp73 
isoforms; whereas transcription initiated from a 
downstream promoter results in the expression of 
N-terminal truncated isoforms missing the transactivation 
domain (ΔNp73) [1, 4]. Additional isoforms (α,β,γ,δ) are 
generated by C-terminal differential splicing [1, 4, 5]. 
Recently, we demonstrated that TAp73 acts as a tumor 
suppressor and its depletion results in a tumor prone 
phenotype [6]. On the contrary, ΔNp73 has oncogenic 
properties and transformed fibroblasts lacking ΔNp73 fail 
to grow when injected into immunocompromised mice 
[7]. The ability of TAp73 to suppress tumor formation 
depends on several mechanisms, including its ability to 
induce cell cycle arrest [8] and apoptosis [9–18] through 
regulation of target genes partially shared with p53 
[19–23], such as p21 [24–27], PUMA [28–32] and BAX 
[33, 34]. These findings notwithstanding, data on humans 
show that, conversely to p53 [35–41], TAp73 is rarely 
mutated in cancer and its expression is often retained [1, 
3, 42, 43], suggesting a more complex scenario for p73 
in cancer.
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Over the past decade, the metabolic adaptation 
of tumor cells has attracted increasing appreciation 
as main drivers of cancer growth. Cancer cells adopt 
their metabolism to sustain high rate of cell growth and 
proliferation and to survive a hostile environment. This 
alteration is necessary to satisfy metabolic demands 
including maintenance of elevated cellular ATP levels, 
active biosynthesis of macromolecules and preservation 
of the cellular redox equilibrium [44–48]. The change in 
glucose metabolism known as Warburg effect or aerobic 
glycolysis is probably the most characterized metabolic 
adaptation of cancer cells, which show sustained glucose 
consumption and glycolytic rate. Additional metabolic 
adaptations have been described for amino acid [49, 50] 
and lipid metabolism [51, 52], demonstrating an extensive 
metabolic rewiring that underpins tumorigenesis, and 
nurturing the idea that therapeutic interventions targeting 
metabolism could benefit cancer patients [53–58].
Of note, we have recently demonstrated that TAp73 
regulates energetic and oxidative metabolism through 
modulation of mitochondrial function: we showed that 
depletion of TAp73 impairs activity of the complex IV 
of the electron transport chain, decreases mitochondrial 
respiration and intracellular ATP and increases ROS 
content [59, 60]. Moreover, we unveiled a role for TAp73 in 
regulating enzymes of serine-glycine metabolism in cancer 
cells [61] and lipid metabolism in hepatic cells [62]. Shortly 
after, Du and colleagues showed that glucose-6-phosphate 
dehydrogenase (G6PD), the rate-limiting enzyme in the 
pentose phosphate pathway (PPP) is a TAp73 target gene 
[63]. Though enhanced G6PD expression, TAp73 fuels the 
PPP leading to increase ribose and NADPH biosynthesis, 
with the final outcome of reducing cellular ROS and 
promoting cellular proliferation [63]. These last findings 
have challenged the common knowledge that TAp73 
is a tumor suppressor [1] and suggested that it regulates 
metabolism in order to sustained cell replication.
Prompted by these results, we attempted to 
further elucidate the regulation of cellular metabolism 
by p73 performing high throughput metabolomics 
study upon ectopic expression of TAp73 in human p53-
null osteosarcoma cell lines (SaOs-2). Here we report 
an interesting role for TAp73 in promoting anabolic 
metabolism, including increased synthesis of acetyl-CoA, 
polyamines, and membrane phospholipids. Moreover, 
our data suggest that TAp73 promotes glycolysis and 
enhances the Warburg effect. Finally, we uncovered 
additional regulations impinging on the methyl donor 
S-adenosyl-methionine (SAM), fatty acids and arginine-
proline metabolism.
Overall, our findings demonstrate that TAp73 
activates anabolic pathways compatible with proliferation 
and in line with the report from Du and colleagues. 
Notwithstanding, we deem the current data insufficient to 
question the tumor suppressive function of TAp73, which 
we consistently detect through robust activation of p21 
and induction of apoptosis. Our findings should also be 
interpreted on the light of the multifaceted physiological 
activities of p73, including regulation of animal aging, 
senescence, neurodegerative diseases and fertility [59, 
64, 65].
RESULTS
To investigate the effects of TAp73 expression 
on cellular metabolism, we used human p53/p73 null 
SaOs-2 osteosarcoma cell line, engineered to overexpress 
human HA-tagged TAp73 isoforms when cultured in the 
presence of the tetracycline analog doxycycline (Dox) [29] 
(Supplemental Figure 1). TAp73 has been reported to 
halt cell proliferation and to induce apoptosis [1, 16, 28]. 
Hence, to avoid unwanted effects on metabolic profiling 
caused by induction of cell cycle arrest or cell death, 
we carefully investigated the outcome of p73 induction 
over 72h time course. In our system, expression of both 
TAp73α C-terminal isoforms reached plateau after 16h of 
Dox treatment, without any discernible effect on cell cycle 
distribution (Supplemental Figure 1A and B). Of note, the 
p73 direct target p21 was also upregulated, indicating 
that p73 is transcriptionally active at the same time point 
(Supplemental Figure 1A). Next, we measured induction 
of cell death as sub-G1 peak. Expression of TAp73α 
isoform induced considerable apoptosis in late time points, 
starting at 24h after Dox addition. Importantly, similarly 
to cell cycle profile, early time points show no difference 
in cell survival when compared to untreated controls, 
whereas sustained cell death was observed at later time 
points (Supplemental Figure 1C).
Taken together, these data indicate that short 
time induction of TAp73 (8h and 16h) results in robust 
expression, engagement of transcriptional activity, with no 
overt effect on cell cycle and cell survival. Consequently, 
we decided to perform metabolomics profiling in SaOs-2 
cell line at early time points (8h and 16h) after induction 
of TAp73β. We focused on the C-terminal β isoforms 
because of its stronger transcriptional activity, but affects 
cell cycle and survival similarly to TAp73α (not shown). 
The main predictable bias is that a short induction might 
not be sufficient for completion of elaborated metabolic 
pathways triggered or inhibited by TAp73. Regardless, 
we reasoned that changes in a subset of metabolites may 
suffice in identifying significant metabolic rearrangements 
triggered by p73.
We used GC-MS and LC-MS-MS platforms for 
metabolomic studies of TAp73β SaOs-2 Tet-on treated 
with vehicle or with 2μg/ml doxycycline for 8h and 16h. 
This approach enabled detection of 292 biochemical 
compounds, a fraction of which showed significant 
differences between the different groups (uninduced, 
8h and 16h). 15% to 20% of all detected biochemicals 
displayed statistical significant differences ( p < 0.05, 
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Welch’s, two samples, t-test), between uninduced and 
induced samples (Table 1), whereas changes in 10% of the 
compounds approached statistical significance (0.05 < p < 
0.1).
Glucose metabolism through glycolysis assumes 
substantial relevance in cancer. One of the hallmarks of 
many cancer cells is the high rate of glucose consumption 
and its conversion into lactate even in the presence of 
oxygen (known as aerobic fermentation, or Warburg 
effect) [44]. Though still object of intense investigation 
and debate, the Warburg effect is important to increase 
energy production and to enrich the cellular milieu with 
glycolytic intermediates used in biosynthesis pathways 
necessary to sustain proliferation [44]. Strikingly, 
expression of p73 produced a decrease in intracellular 
glucose and pyruvate levels with a concomitant 
increase in lactate (Figure 1). This suggests that TAp73 
is a positive regulator of glycolysis and enhances the 
Warburg effect. Consistent with enhanced glycolytic 
flux, we also detected increased amount of acetyl-CoA 
and citrate (Figure 1). Of note, citrate was the only TCA 
cycle metabolites to be consistently increased (data not 
shown). It is possible that 16h are not enough for the 
build-up of other TCA cycle intermediates, or anaplerotic 
reactions may contribute to stabilize the TCA cycle 
activity. Alternatively, citrate could be shunt to fatty acid 
biosynthesis instead of entering Krebs’s cycle, although 
we did not observed increased free fatty acids at 16h post-
induction. On the other hand, the increase in acetyl-CoA, 
correlated with an overall increase in the biosynthesis of 
coenzyme A (CoA), as suggested by the slight decrease in 
its biochemical precursors in treated cells (Supplemental 
Figure 2). CoA is a pivotal cofactor essential for anabolic 
pathways involved in lipid, amino acid and carbohydrate 
metabolism: its augmented levels suggest increased 
metabolic rate in TAp73 expressing cells.
Another relevant observation, and one of the most 
consistent changes, was a significant higher level of amino 
acids and amino acid metabolites in Dox-treated samples 
(Figure 2). This can be interpreted as increased uptake of 
metabolites from the culture media and suggests increased 
metabolic activity as a result of p73 induction.
Moreover, we detected elevated levels of compounds 
involved in membrane biosynthesis in induced cells, 
including choline phosphate and phosphoethanolamine 
(Figure 3).
TAp73 also regulates polyamines metabolism, 
inducing their synthesis. Indeed, ornithine, putrescine 
and spermidine were significantly upregulated 8h after 
TAp73 induction (Figure 4) and 5-methylthioadenosine, 
the byproduct of spermidine and spermine biosynthesis, 
was also consistently upregulated. Polyamines are 
essential for cell proliferation and their metabolism 
is increased by oncogenes [66]. Indeed, targeting 
polyamines biosynthesis is regarded as a potential 
anticancer therapy [66]. Thus, these data reinforce the 
idea that TAp73-mediated metabolic rewiring sustains 
anabolic pathways.
Arginine metabolism through Urea cycle leads 
to proline, whose hydroxylation is an important step in 
collagen synthesis. We observed a significant increase in 
hydroxyproline and proline-hydroxyproline in induced 
cells, suggesting extracellular matrix remodeling triggered 
by TAp73 (Supplemental Figure 3).
Of note, our data also suggest that TAp73 might be 
involved in epigenetic changes. On one hand, we have 
described increased levels of acetyl-CoA (Figure 2 and 
Supplemental Figure 2), by far the main acetyl donor in 
the cell. On the other hand, we also detected a significant 
increment in the methyl-donor SAM, which correlated 
with a more modest increase in its demethylated 
byproducts S-adenosylhomocysteine (SAH) and 
cystathionine (Figure 5). Cystathionine is further 
metabolized to the amino acid cysteine, which shows a 
robust accumulation in induced cells (Figure 5). Although 
we cannot exclude that such increase could result from 
enhanced cellular uptake. Finally, an upward trend in 
methylated compounds such as 5-methyltetrahydrofolate 
(5MeTHF) and methylphosphate, supports an overall 
surge in methylation triggered by TAp73 (Figure 5).
TAp73-expressing cells exhibit a significant 
accumulation of carnitine conjugates of fatty acids 
(Supplemental Figure 4). Fatty acids are imported in 
the mitochondria as acyl conjugates and formation of 
Table 1: Significantly metabolic alterations identified in SaOs-2 cells after TAp73 over expression. 
SaOs-TAp73β Dox 8h vs CTRL Dox 16h vs CTRL Dox 16h vs Dox 8h
Biochemicals p ≤ 0.05 55 (54/1) 42 (34/8) 17 (7/10)
Biochemicals 0.05 ≤ p ≤ 0.10 30 (26/4) 28 (15/13) 17 (5/12)
Significantly altered metabolites in SaOs-Tet-on. Red indicates number of upregulated compounds, whereas green indicates 
downregulation. Following log transformation and imputation with minimum observed values for each compound, Welch’s 
two-sample t-test was used to identify biochemicals that differed significantly between doxycycline-induced sample groups 
compared to control (no doxycycline), as well as identifying significant biochemical migration as induction progresses from 
eight to sixteen hours of doxycycline exposure. An estimate of the false discovery rate (q-value) is calculated to take into 
account the multiple comparisons that normally occur in metabolomic-based studies; as q-values were reasonable for p ≤ 0.05, 
no q-value cutoff was established.
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acyl-carnitines is a limiting step in fatty acids oxidation. 
The reason for this build-up is unclear. Possibly, TAp73 
induction is blocking β-oxidation, as suggested by the 
observed increment in carnitine β-oxidation intermediates. 
Alternatively, carnitine conjugates of fatty acids may 
be used for different metabolic processes (for example 
membrane biosynthesis).
To predict the possible gene/metabolite network, 
underlining the metabolomics effects of TAp73, 
we implemented a statistical procedure based on 
our current knowledge of signalling and metabolic 
pathways. We used all the metabolites resulted 
upregulated in our analysis, plus KEGG and Reactome 
databases to construct integral gene-metabolite 
network [67–69]. We used the integral network to 
compute the distance between a metabolite and p73. 
The distance was computed as a minimal number of 
steps on the network needed to get from p73 to the 
metabolite. Only 2 measured metabolites (glutamine 
and glutamate) were located within 2 steps from p73 
and both are unregulated (Table 2, and Figure 6). 
Nine up-regulated metabolites (out of 33) resulted 
located within 4 steps, while only 7 (out of 160) of not 
up-regulated metabolites are so closed to p73 (Table 2). 
Figure 1: TAp73 enhances glycolytic flux. Increased glycolytic flux as suggested by reduced intracellular glucose and concomitant 
increased lactate and acetyl-CoA. This result suggests that TAp73 expression sustain Warburg effect and might help explaining while its 
expression is retained in many cancers. The decrease pyruvate levels probably reflect channeling into lactate and acetyl-CoA. Of note, the 
augmented acetyl-CoA levels may also stem for increased biosynthesis. **p < 0.05; *0.05 < p < 0.1.
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Interestingly this computational analysis highlighted 
the importance in the overall p73-dependent metabolic 
changes of glutaminolysis. TAp73 regulation on GLS-
2 [70, 71], indeed, might widely modulate the entire 
aminoacids metabolism, beside the simple conversion 
of glutamine in glutamate (Figure 6). As consequences 
of GLS-2 regulation, TAp73 appears to indirectly 
affect aspartate, alanine, valine, leucine and isoleucine, 
up to 4–5 nodes of distance (Figure 6). However, this 
prediction is based on the current limited knowledge 
of p73-metabolic enzyme connections (Figure 6). In 
conclusion, this analysis confirms p73 effects on cell 
metabolism and provides a potential explanation at least 
for part of these effects.
DISCUSSION
Oncogenes reprogram metabolism to sustain 
cell growth, whereas tumor suppressors halt 
malignancy also by mean of metabolic regulation. 
The awareness of the intense metabolic rewiring in 
cancer has stimulated research to unravel its origin and 
regulation. Recent work has also demonstrated that 
the p53 family plays an important role in regulating 
metabolism in different settings [59, 61, 63, 70, 72–76] 
and suggests that metabolic regulation contributes 
to the vast complexity of the p53 family functions, 
including cell death [77–81], redox homeostasis 
[82], development [83–87], senescence [88–90], 
aging [91–94] and fertility [95–97]. For this reason, we 
Figure 2: Increased amino acid uptake in TAp73 expressing cells. Increased intracellular contents of numerous amino acids after 
short-time induction of TAp73β, probably reflecting increased uptake from culture medium. This upward trend on intracellular amino acid 
content reflect an overall increase in anabolism upon induction of TAp73. All metabolomics data are represented as box plot, with upper 
and lower quartile, max and min distribution values and median value.
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sought to investigate whether TAp73 regulates metabolism 
and how this could relate to physiological roles. With this 
in mind, we performed a high throughput metabolic study 
of osteosarcoma cells expressing tetracycline-inducible 
TAp73β. Through careful cell cycle and survival analysis, 
we were able to establish that induction of TAp73 for 
8h and 16h resulted in abundant protein expression 
and engagement of transcriptional activity without any 
significant effect on cell proliferation and apoptosis. 
Hence, we exclude that our results are biased by p73 pro-
apoptotic and anti-proliferative activities evident at later 
time points after TAp73 induction.
Interestingly, we found that expression of TAp73 
modulates numerous metabolites with the net result of 
increasing cellular biosynthetic pathways and promoting 
glucose consumption and Warburg effect, a metabolic 
hallmark of cellular transformation [44, 98]. This last effect 
appears  to be in striking contrast to p53-mediated inhibition 
of glycolytic flux [99]. Moreover, TAp73-expressing cells 
show increased amino acid uptake and increased levels of 
acetyl-CoA indicative of increased metabolic rate. Similarly, 
we detected increased biosynthesis of polyamines, as 
observed in proliferating and cancerous cells.
Therefore, it appears that, despite TAp73 is able to 
trigger a molecular program to arrest cell proliferation and 
induce apoptosis (i.e. upregulation of PUMA and p21) [28], 
it does promote a metabolic rearrangement that is reminiscent 
of an opposite, pro-growth and pro-proliferative outcome. 
This possibility was also suggested by a recently published 
manuscript reporting that TAp73 sustains proliferation 
through regulation of the PPP [63]. Du and colleagues show 
that TAp73-mediated expression of G6PD diverts glucose 
metabolism towards PPP and production of NADPH, which 
is required for ROS detoxification [100–104] and ribose 
for nucleotide biosynthesis and proliferation. Despite we 
report an increase rate of glucose metabolism, we did not 
observe evident differences in PPP. We did indeed record 
a striking increase in nucleotides levels in p73 expressing 
Saos-2 (manuscript in press), somehow in line with the pro-
proliferative activity of TAp73 reported by Du and colleagues 
Figure 3: TAp73 regulates biosynthesis of phospholipids. Expression of TAp73β induces biosynthesis of membrane lipids, 
including a substantial increase in phosphoethanolamine. The data also suggest that increased cytidine 5’-monophosphate may partially 
results from enhanced lipid membrane biosynthesis, through conversion of diacylglycerol to phosphatidylcholine. **p < 0.05.
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[63]. However, different interpretations might be applied to 
TAp73-depedent nucleotide biosynthesis. Being relevantly 
involved in DNA-damage response [105–113], TAp73 might 
also promote nucleotide biosynthesis in order to provide 
sufficient substrates to the DNA-repair machinery. In their 
study, Du and colleagues observed a substantial reduction 
of tumour proliferation in mouse xenograft tumour models 
after TAp73 knockdown, however this observation was not 
confirmed in other xenograft models [114], and contradicted 
by the tumourigenesis of TAp73-/- mice [6].
Overall, these findings bear several implications. 
Firstly, the operational definition of tumor suppressor might 
be misleading and might be unable to fully categorize 
genes. TAp73 regulation of metabolism should be 
interpreted on the light of its multifaceted activities, which 
include roles in fertility, development, neurodegeneration 
and aging [4, 22, 59, 64, 65, 115], beyond its function in 
cancer. Intriguingly, we and others have shown that lack 
of TAp73 compromise growth and maintenance of neural 
stem cells [64, 116]. The findings reported here prompt 
the intriguing possibility that impaired metabolism might 
underline the defect in stem cells maintenance after 
depletion of TAp73 and contribute to the neurodegerative 
outcome of p73 loss [117–119]. Moreover, we have 
provided evidence that loss of TAp73 leads to senescence 
and aging in knockout animals. We were able to correlate 
these phenotypes with decreased mitochondrial activity, 
enhanced ROS production and a marked sensitivity to 
oxidative stress. Nonetheless, the anabolic metabolism 
promoted by TAp73 might ultimately contribute to 
prevent accelerated senescence and aging, a possibility that 
warrants further investigation. This interpretation of the 
data would also reconcile TAp73 with its repeatedly proved 
role as tumor suppressor, a function that we have not failed 
to confirm in the present study, showing induction of p21 
and apoptosis upon expression of TAp73.
Figure 4: Enhanced polyamines biosynthesis induced by TAp73. Polyamines show a significant increase after 8h of TAp73β 
induction. Ornithine, putrescine and spermidine are all upregulated. Polyamine expression has been linked to proliferation and polyamine 
biosynthesis pathway is highly regarded for anticancer therapy. This increase is not maintained at 16h induction and the reason for this is 
currently unknown. **p < 0.05.
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In this analysis we have identified additional 
metabolic changes. We report a sustained arginine 
metabolism in TAp73 expressing cells, which suggests 
a possible rearrangement of the extracellular matrix 
(ECM) environment. The recent discovery that p63 
suppress cell motility and invasion [120–123], also 
suggests (i) that p73 might regulates cell motility 
through ECM rearrangement and (ii) that p63 might 
share a similar ability to regulate arginine metabolism 
and, possibly, ECM.
Also worth investigation is the finding of augmented 
SAM levels, which might link TAp73 to epigenetic 
rearrangement. If demonstrated, this possibility would 
reinforce the growing awareness that regulation of 
metabolism impacts cellular physiological processes, such 
as epigenetic and gene expression.
Further studies are necessary to address which 
genetic program underlines TAp73-mediated regulation 
of cellular metabolism and to understand how this 
applies to cancer and affects the phenotypes triggered 
by p73 depletion. Nonetheless, our work has unveiled an 
unexpected role for TAp73 in promoting anabolism and 
has clearly established a divergence between p53 and p73 
in the regulation of cellular metabolism.
Figure 5: TAp73 expression affects the methionine cycle. A significant increment in the methyl-donor SAM correlates with an increase 
in its demethylated byproducts S-adenosylhomocysteine and cystathionine. Cysteine, the downstream metabolic product of cystathionine, also 
shows a robust accumulation in induced cells; although we cannot exclude that cysteine accumulation results from increased uptake from growth 
medium. Finally, we detected an upward trend in the methylated compound 5-methyltetrahydrofolate. Overall these changes suggest that TAp73 
might regulate 1-carbon metabolism and epigenetic through availability of the methyl donor SAM. **p < 0.05; *0.05 < p < 0.1.
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MATERIALS AND METHODS
Cells culture
SaOs-2 Tet-On inducible for TAp73 were cultured 
at 37 °C in 5% CO2 in RPMI 1640 medium (Gibco), 
supplemented with 10% FCS, 250 mM L-glutamine, 
penicillin/streptomycin (1 U/ml), and 1 mM pyruvate 
(all from Life Technologies). TAp73 expression was induced 
by addition of doxycycline 2μg/ml for the indicated time.
Western Blots
Proteins were extracted from cell pellets using RIPA 
buffer (25mM Tris/HCl pH 7.6, 150mM NaCl, 1% NP-40, 
1% sodium deoxycholate, 0.1% SDS) supplemented with 
Table 2: Summary of metabolic network identified in SaOs-2 cells after TAp73 over expression.
Distance Odds Ratio Up regulated  
(33 is a number of 
upregulated)
All other  
(160 is a number of all 
measured metabolites 
excluding 33 up regulated)
p-value (fisher test)
2 N/A (∞)  2 (out of 33)   0 (out of 160) ~0.03
4 6.2  9 (out of 33)   7 (out of 160) ~ 0.001
5 4.5 13 (out of 33)  14 (out of 160) ~0.001
7 3.4 17 (out of 33)  24 (out of 160) ~ 0.01
10 1.2 33 (out of 33) 126 (out of 160)   0.23
The table provides statistics on the number of metabolites that located on integral network within a fixed distance from p73. 
Odds ratio indicates enrichment of metabolites located within 4 steps to p73 among unregulated metabolites quantitatively: 
(9/33) / (7/160) ~ 6.2. Fisher test indicates that a probability to get similar or better enrichment randomly selecting 33 
metabolites out of 193 measured is less than 1 in 1000.
Figure 6: Genes/metabolites network affected by TAp73 Prediction of the gene/metabolite network affected by 
TAp73. In this network, a node is a gene or a metabolite. Edge between genes means that there is a signalling pathway where the genes 
are connected (transfer signal, interacts or a part of the same protein complex). Edge between a gene and a metabolite means that the gene 
product is enzyme known to catalyse the metabolite biotransformations.
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phosphatase and protease inhibitor cocktails (ROCHE). 
Quantification of protein extracts was performed using BCA 
protein assay from PIERCE. 40μg of protein were boiled 
for 6 minutes at 90°C and then separated using SDS-PAGE, 
transferred to nitrocellulose membranes using standard 
transfer techniques and blocked with 5% milk for 2h at room 
temperature. Primary antibodies were incubated O/N at 4°C 
in blocking with gentle agitation. We used rabbit HA (Santa 
Cruz, Y11), rabbit β-tubulin (Santa Cruz, H-135), rabbit 
p21 (H-164). Horseradish peroxidase (HRP)-conjugated 
secondary antibodies (BioRad) and ECL chemoluminescence 
substrate (PIERCE) were used for final detection.
Metabolic analysis
TAp73 SaOs-2 Tet-On cell lines were cultured 
in growing medium and treated for 8h and 16h with 
doxycycline 2μg/ml to induce TAp73β expression. Control 
cells were treated with vehicle (PBS) for 16h. Thirty 
million cells were spun down and pellets were washed 
once with cold PBS before being frozen in dry ice. All the 
samples were extracted using standard metabolic solvent 
extraction methods and analyzed through GC/MS and LS/
MS as previously described [124].
Cell cycle and survival
For cell cycle analysis 500,000 cells were treated 
for the indicated time with doxycycline 2μg/ml, collected 
and fixed with ice cold 70% ethanol. After O/N fixing at 
-20°C, cells were washed in PBS, resuspended in 50μl 
of 10μg/ml RNase solution (SIGMA) and incubated for 
10 minutes at 37°C. 500μl of staining solution (50μg/ml 
propidium iodide in PBS) was added to the cells, followed 
by additional incubation 30 minutes at 37°C. Stained cells 
were analyzed by flow cytometry and at least 10,000 cells 
per sample were collected. Data were analyzed using 
CELLQuest acquisition/analysis software.
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